Compare KGEI & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KGEI | CDXS |
|---|---|---|
| Founded | 2008 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Major Chemicals |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.1M | 141.8M |
| IPO Year | N/A | 2010 |
| Metric | KGEI | CDXS |
|---|---|---|
| Price | $4.11 | $1.82 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | 71.3K | ★ 1.5M |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.99 | N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $60,121,000.00 | $52,932,000.00 |
| Revenue This Year | $6.94 | $15.64 |
| Revenue Next Year | $14.53 | $5.23 |
| P/E Ratio | $8.31 | ★ N/A |
| Revenue Growth | ★ 10.00 | N/A |
| 52 Week Low | $3.71 | $1.52 |
| 52 Week High | $9.89 | $6.08 |
| Indicator | KGEI | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 49.79 | 46.48 |
| Support Level | $3.94 | $1.62 |
| Resistance Level | $4.11 | $1.79 |
| Average True Range (ATR) | 0.15 | 0.10 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 89.72 | 93.44 |
Kolibri Global Energy Inc is a North American energy company focused on finding and exploiting energy projects in oil, gas, and clean and sustainable energy. It is focused on the acquisition, exploration, and production of oil and gas reserves. The company owns and operates shale oil and gas properties in the United States. The company derives a majority of its revenue from the United States.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.